Sistema de Información Esencial en Terapéutica y Salud


Última actualización: 18/6/2018
SIETES contiene 92381 citas

 1 a 20 de 316 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Watanabe JH, McInnis T, Hirsch JD. Cost of prescription drug-related morbidity and mortality.. Annals of Pharmacotherapy 2018:26 de marzo. [Ref.ID 102573]
2. Cita con resumen
Schuchat A, Houry D, Guy Jr GP. New data on opioid use and prescribing in the United States. JAMA 2017;318:425-6. [Ref.ID 102055]
4. Cita con resumen
Rubin R. GAO reports costs of new Medicare Part B drugs in 2013. JAMA 2016;315:122. [Ref.ID 99972]
5.Tiene citas relacionadas Cita con resumen
Meier F, Maas R, Sonst A, Patapovas A, Müller F, Plank-Kiegele B, Pfistermeister B, Schöffski O, Bürkle T, Dormann H. Adverse drug events in patients admitted to an emergency department: an analysis of direct costs. Pharmacoepidemiol Drug Saf 2015;24:176-86. [Ref.ID 99600]
6. Cita con resumen
Avorn J. The $2.6 billion pill — Methodologic and policy considerations. N Engl J Med 2015;372:1877-9. [Ref.ID 99114]
7. Cita con resumen
Freedberg DE, Salmasian H, Abrams JA, Green RA. Orders for intravenous proton pump inhibitors after implementation of an electronic alert. JAMA Intern Med 2015;175:452-4. [Ref.ID 98971]
8. Cita con resumen
Scott DL, Ibrahim F, Farewell V, O'Keeffe AG, Walker D, Kelly C, Birrell F, Chakravarty K, Maddison P, Heslin M, Patel A, Kingsley GH. Tumour necrosis factor inhibitors versus combination intensive therapy with conventional disease modifying anti-rheumatic drugs in established rheumatoid arthritis: TACIT non-inferiority randomised controlled trial. BMJ 2015;350:h1046. [Ref.ID 98857]
9. Cita con resumen
Anónimo. Study: cost to develop, bring a drug to market about $2.6B. DIA Daily 2014:19 de noviembre. [Ref.ID 98334]
11. Cita con resumen
Roth JA, Etzioni R, Waters TM, Pettinger M, Rossouw JE, Anderson GL, Chlebowski RT, Manson JE, Hlatky M, Johnson KC, Ramsey SD. Economic return from the Women's Health Initiative estrogen plus progestin clinical trial. A modeling study. Ann Intern Med 2014;160:594-602. [Ref.ID 97572]
12.Enlace a cita original Cita con resumen
Cahir C, Bennett K, Teljeur C, Fahey T. Potentially inappropriate prescribing and adverse health outcomes in community dwelling older patients. Br J Clin Pharmacol 2014;77:201-10. [Ref.ID 96998]
13. Cita con resumen
Spijker J, MacInnes J. Population ageing. The timebomb that isn't?. BMJ 2013;347:20-2. [Ref.ID 96701]
14. Cita con resumen
Hayes JH, Ollendorf DA, Pearson SD, Barry MJ, Kantolff PW, Lee PA, McMahon PM. Observation versus initial treatment for men with localized, low-risk prostate cancer: a cost-effectiveness analysis. Ann Intern Med 2013;158:853-60. [Ref.ID 95679]
15. Cita con resumen
16. Cita con resumen
Gómez Arrayas I, Suárez Fernández C, Gómez Cerezo JF, Betegón Nicolás L, de Salas-Cansado M, Rubio-Terrés C. Impacto presupuestario para el Sistema Nacional de Salud de la prevención del tromboembolismo venoso con apixaban en pacientes sometidos a artroplastia total de rodilla o cadera. Rev Esp Salud Pública 2012;86:601-12. [Ref.ID 93269]
17.Tiene citas relacionadas Cita con resumen
Gale E. Post-marketing studies of new insulins: science or sales?. BMJ 2012;344:24-7. [Ref.ID 93248]
18. Cita con resumen
Anónimo. Best care at lower cost: the path to continuously learning health care in America. Institute of Medicine of the National Academies 2012:6 de septiembre. [Ref.ID 92937]
19. Cita con resumen
Gyllensten H, Jönsson AK, Rehnberg C, Carlsten A. How are the costs of drug-related morbidity measured? A systematic literature review. Drug Saf 2012;35:207-19. [Ref.ID 92431]
20. Cita con resumen
Donohue JM, Morden NE, Gellad WF, Bynum JP, Zhou W, Hanlon JT, Skinner J. Sources of regional variation in Medicare Part D drug spending. N Engl J Med 2012;366:530-8. [Ref.ID 92341]
Seleccionar todas
 1 a 20 de 316 siguiente >>